International Searching and Preliminary Examining Authorities

Kane Biotech Receives Decisions to Grant for Two European Patents Providing Broad Protection of coactiv+™ Technology for Wound Care, Skin Infections and Personal Care Formulations

Retrieved on: 
Thursday, July 29, 2021
Intellectual property law, Patent offices, International Searching and Preliminary Examining Authorities, European Patent Organisation, Patent examiner, Patent portfolio, European Patent Office

The allowed claims cover composition of matter for the company's proprietary formulations for use in treating wounds and skin infections and in personal care formulations.

Key Points: 
  • The allowed claims cover composition of matter for the company's proprietary formulations for use in treating wounds and skin infections and in personal care formulations.
  • A Decision to Grant is the European Examiners confirmation that the European Patent Office has decided to grant Kane the patent and has set the grant date.
  • "These patents are important additions to the existing portfolio covering Kanes coactiv+ technology platform," saidGordon Guay, the company's Chief Scientific Officer.
  • Its multi-functional and gentle formulation makes it a perfect companion treatment to DispersinB Hydrogel, also part of the Kane Biotech antibiofilm wound care portfolio.

GBT - 3D CHIP and MEMORY Patent Will Be Published in Europe

Retrieved on: 
Wednesday, July 21, 2021
Intellectual property law, Countries, Government, European Patent Organisation, International Searching and Preliminary Examining Authorities, Patent offices, Gazettes, Patent, European Patent Convention, United States Patent and Trademark Office, European Patent Bulletin

SAN DIEGO, July 21, 2021 (GLOBE NEWSWIRE) -- GBT   Technologies   Inc.   ( OTC PINK: GTCH ) ("GBT” or the “Company”), is pleased to report the upcoming publication of its 3D CHIP and MEMORY patent in Europe on July 28, 2021. The application has been allocated the number 19862631.9 and designates all European Patent Convention (“EPC”) states, as of the Patent Cooperation Treaty (“PCT”) filing date.

Key Points: 
  • SANDIEGO, July 21, 2021 (GLOBE NEWSWIRE) -- GBT Technologies Inc. ( OTC PINK: GTCH ) ("GBT or the Company), is pleased to report the upcoming publication of its3D CHIP and MEMORY patent in Europe on July 28, 2021.
  • The application has been allocated the number 19862631.9 and designates all European Patent Convention (EPC) states, as of the Patent Cooperation Treaty (PCT) filing date.
  • The companys 3D microchip patent was filed on March 5, 2019 and was granted as of December 1, 2020 by the United States Patent and Trademark Office (USPTO); U.S. Patent No.
  • The bibliographic data of the above-mentioned Euro-PCT application will be published on28.07.21 in Section 1.1 of the European Patent Bulletin.

TrippBio receives Notice of Allowance from the U.S. Patent Office for Therapeutic Treatment of COVID-19 Infections

Retrieved on: 
Thursday, July 15, 2021
Intellectual property law, Patent offices, International Searching and Preliminary Examining Authorities, Patent law, European Patent Organisation, United States Patent and Trademark Office, Patent application, Patent office, European Patent Office, Term of patent

JACKSONVILLE, Fla., July 15, 2021 /PRNewswire-PRWeb/ --TrippBio, Inc. (TrippBio), a clinical development-stage company developing antiviral treatments with an initial focus on COVID-19, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent application No.

Key Points: 
  • JACKSONVILLE, Fla., July 15, 2021 /PRNewswire-PRWeb/ --TrippBio, Inc. (TrippBio), a clinical development-stage company developing antiviral treatments with an initial focus on COVID-19, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent application No.
  • 16/875,487, and the European Patent Office (EPO) has issued a favorable opinion in a counterpart European application.
  • The availability of safe and effective treatment options can reduce the rate of hospitalizations and hopefully the long-term effects of COVID-19."
  • TrippBio is founded on the scientific research of Ralph Tripp, Ph.D., Georgia Research Alliance Chair and professor at the University of Georgia.

US Patent and Trademark Office Grants Patent to Ventegra for Its Acquisition Cost Index (ACI) Cost-Plus Pricing Reimbursement Technology Platform for Prescription Drugs

Retrieved on: 
Tuesday, July 13, 2021
Software, Practice Management, Pharmaceutical, Managed care, Health, Data management, Hospitals, Technology, Intellectual property law, Patent offices, Intellectual property organizations, International Searching and Preliminary Examining Authorities, United States patent law, United States Patent and Trademark Office, Patent and Trademark Office, Patent

The US Patent and Trademark Office (USPTO) has granted US patent number 11,023,979 B2 (June 1, 2021) that covers Ventegras Acquisition Cost Index (ACI) cost-based reimbursement technology (Reference Price Index) through 2034.

Key Points: 
  • The US Patent and Trademark Office (USPTO) has granted US patent number 11,023,979 B2 (June 1, 2021) that covers Ventegras Acquisition Cost Index (ACI) cost-based reimbursement technology (Reference Price Index) through 2034.
  • The technology makes it possible to replace antiquated reimbursement practices, certifying that clients are billed the same amount as the pharmacy was paid.
  • By updating prescription costs daily and eliminating disputes from pharmacies about reimbursement, the ACI renders obsolete manually derived cost lists.
  • Adds Taketomo, We are pleased that the US Patent Trademark Office has recognized the uniqueness of our Ventegra ACI technology and granted this patent.

CytoDyn Granted a Significant Patent by USPTO for Methods of Treating Coronavirus Infection with Leronlimab

Retrieved on: 
Tuesday, July 6, 2021
Intellectual property law, International Searching and Preliminary Examining Authorities, Patent offices, Patent application, United States Patent and Trademark Office, Patent, United States patent law, Outline of patents

11,045,546 by the U.S. Patent and Trademark Office (USPTO) for methods of treating coronavirus infection (the Patent).

Key Points: 
  • 11,045,546 by the U.S. Patent and Trademark Office (USPTO) for methods of treating coronavirus infection (the Patent).
  • The Patent is owned by CytoDyn and its term of protection is expected to extend at least until June 15, 2040.
  • The USPTO prioritized examination of CytoDyns patent application, resulting in the grant of this Patent under the USPTOs COVID-19 Prioritized Examination Pilot Program in just about one (1) year.
  • The Patent discloses methods of treating hyperinflammationa common complication of COVID-19 caused by SARS-CoV-2 coronavirus infection.

U.S. Patent & Trademark Office Issues Patent to ComplianceMate® for Innovative Food Safety Management System

Retrieved on: 
Friday, June 4, 2021
Intellectual property law, International Searching and Preliminary Examining Authorities, Patent offices, Food safety, Food science, Product safety, Patent, United States Patent and Trademark Office

LAWRENCEVILLE, Ga., June 3, 2021 /PRNewswire/ --CM Systems LLC, (ComplianceMate), a leader in Food Safety Technology and Automation, announced the United States Patent and Trademark Office issued U.S. Patent No.

Key Points: 
  • LAWRENCEVILLE, Ga., June 3, 2021 /PRNewswire/ --CM Systems LLC, (ComplianceMate), a leader in Food Safety Technology and Automation, announced the United States Patent and Trademark Office issued U.S. Patent No.
  • 11,004,020 to ComplianceMatefor its Digital Food Safety Management System.
  • 9,811,788 to ComplianceMate in 2017 for the various embodiments of a food safety management system, including a web portal for management and reporting, and a handheld computing device for checklist completion.
  • The granting of this patent underscores our commitment to the industry and enhances our position as a leader in the Food Service marketplace," said Steve Getraer,President of ComplianceMate.

Palatin Announces U.S. Patent Term Extension for Vyleesi® (bremelanotide injection)

Retrieved on: 
Tuesday, May 4, 2021
Intellectual property law, Patent law, Term of patent in the United States, United States patent law, Intellectual property organizations, Term of patent, International Searching and Preliminary Examining Authorities, Patent offices, Bremelanotide, Drug Price Competition and Patent Term Restoration Act, United States Patent and Trademark Office, Patent

For more information on Vyleesi, go to www.vyleesi.com .\nThe patent term extension is pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984, commonly called the Hatch-Waxman Amendments, which permits an extension of the term of one patent for a maximum period of five years as compensation for patent term lost during drug development and the FDA regulatory review process.

Key Points: 
  • For more information on Vyleesi, go to www.vyleesi.com .\nThe patent term extension is pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984, commonly called the Hatch-Waxman Amendments, which permits an extension of the term of one patent for a maximum period of five years as compensation for patent term lost during drug development and the FDA regulatory review process.
  • An interim extension for a period of one year from the original expiration date of both patents of June 25, 2020, was granted by the USPTO in May 2020.
  • In the Notices of Final Determination issued by the USPTO, the maximum allowable five-year extension was granted.\nPalatin has filed an Election to extend the patent term of U.S. patent 6,794,489.
  • Palatin is not responsible for updating for events that occur after the date of this press release.\nView original content to download multimedia: http://www.prnewswire.com/news-releases/palatin-announces-us-patent-term...\n'

Lobe Sciences Announces Filing of PCT Application

Retrieved on: 
Thursday, April 29, 2021
Countries, Government, Foreign relations, United States patent law, Patent law, International Searching and Preliminary Examining Authorities, Patent offices, Patent application, Provisional application, Patent, United States Patent and Trademark Office, Post-traumatic stress disorder

PCT filing further strengthens the Company's intellectual property portfolio

Key Points: 
  • "\nThe Company\'s PCT filing includes details that were previously submitted in three separate US provisional patent applications filed with the U.S. Patent and Trademark Office ("USPTO").
  • The PCT is an international patent law treaty which provides a unified procedures for filing patent application to protection inventions in each of its member states.
  • By filing one international patent application under the PCT, the Company can simultaneously seek protection for an invention in 153 countries.\nThe PCT application relates to methods for treating or alleviating symptoms of mild traumatic brain injury ("mTBI"), post-traumatic stress disorder ("PTSD") and mTBI with PTSD via administration of a psychedelic agent in combination with N-acetylcysteine ("NAC").
  • Readers are cautioned that assumptions used in the preparation of the forward-looking statements may prove to be incorrect.

GTX Reports 2020 Financial Summary

Retrieved on: 
Monday, April 5, 2021
Intellectual property law, International Searching and Preliminary Examining Authorities, Patent offices, GTX, Patent and Trademark Office, Global Positioning System

LOS ANGELES CALIFORNIA, April 05, 2021 (GLOBE NEWSWIRE) -- GTX Corp (OTC: GTXO) (GTX or the Company), a pioneer in the field of location based wearable GPS human and asset tracking systems and a supplier of Health and Safety personal protective medical equipment, today announced a summary for the year ended December 31, 2020.

Key Points: 
  • LOS ANGELES CALIFORNIA, April 05, 2021 (GLOBE NEWSWIRE) -- GTX Corp (OTC: GTXO) (GTX or the Company), a pioneer in the field of location based wearable GPS human and asset tracking systems and a supplier of Health and Safety personal protective medical equipment, today announced a summary for the year ended December 31, 2020.
  • In these unprecedented times we want to first and foremost extend our appreciation and gratitude to every GTX stake holder from our employees, vendors, customers, advisors, and shareholders that helped GTX navigate and expand throughout 2020.
  • 2020 was probably our most transformative year since we launched our GPS SmartSoles.
  • During the third quarter of 2020, GTX was issued a new patent by the United States Patent and Trademark Office (USPTO), U.S Patent No.

Farmobile Awarded U.S. Patent for Farm Data Collection and Exchange System

Retrieved on: 
Thursday, April 1, 2021
Software, Mobile, Wireless, Networks, Other Retail, Data management, Specialty, Technology, Agriculture, Natural Resources, Security, Retail, Other Technology, Telecommunications, Intellectual property law, International Searching and Preliminary Examining Authorities, Patent offices, United States Patent and Trademark Office, United States trademark law, Patent, United States patent law

Farmobile LLC , Agricultures Independent Data Company, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No.

Key Points: 
  • Farmobile LLC , Agricultures Independent Data Company, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No.
  • 10,963,825 , entitled Farming Data Collection and Exchange System.
  • The patent is directed to a cloud-based farming data collection and exchange system capable of capturing, processing and sharing machine-generated data while being used for farming operations, such as fertilizing, planting, spraying or harvesting crops on a field.
  • The patented technology enables real-time collection, tracking, monitoring, sharing and monetizing of critically important farming operation data.